The Philadelphia Phillies are one of the hottest teams in trade deadline discussions, but one Colorado Rockies star could end up being the acquisition no one sees coming.
Stay updated with the latest happenings in the Dodgers universe, from a pause in Clayton Kershaw’s rehab to Shohei Ohtani’s award-winning week. Here’s all the headlines you might have missed Monday: Clayton Kershaw Experiences a Setback…
In a recent article listing four bold predictions for the 2024 NFL season, the writer has the Dallas Cowboys making a blockbuster trade and starting fresh at the most important position in sports.
The Boston Bruins resolved their starting goaltender logjam in decisive fashion Monday, trading a former Vezina Trophy winner for a goalie and a draft pick.
The Ottawa Senators are coming off a challenging 2023-24 season that saw them finish second-to-last in the Atlantic Division. However, the Senators have completed a blockbuster trade with the Boston Bruins for a notable upgrade. Ottawa…
The Supreme Court’s decision to hear a challenge to Tennessee’s gender-affirming care ban for minors sets the stage for a potentially blockbuster case implicating transgender protections. It marks the first time the justices will weigh in…
The Los Angeles Dodgers are going to be active at the trade deadline this season. The only question is which teams help president of baseball operations Andrew Friedman get the deal(s) across the finish line, and which players will change…
EVP David Griffin declared the New Orleans Pelicans would operate with a sense of urgency in the league’s talent-acquisition markets this summer. The Western Conference was only getting more difficult and the shortcomings of last year’s…
Earlier this year, nonprofit story consultancy Good Energy teamed up with Colby College’s Buck Lab for Climate and Environment to release a tool to measure the representation of climate change onscreen, dubbed the Climate Reality Check. It…
Alnylam Pharmaceuticals’ stock jumped nearly 40% premarket on Monday after the company released results of a late-stage trial for a heart drug that analysts see competing with a key Pfizer treatment.